A Randomized Controlled Clinical Trial on the Study of Autologous Plasma Enriched with Platelet Growth Factors and Extracorporeal Shock Wave Therapy in the Treatment of Peyronie’s Disease

Authors:

Abstract
Background: The results of conservative methods of treating Peyronie’s disease (PD) do not exceed the placebo effect, and surgical treatment does not always lead to satisfactory outcomes. Aim: to evaluate the safety and effectiveness of using platelet rich plasma (PRP) and extracorporeal shock wave therapy (ESWT) in patients with PD. Materials and Methods: The study included 40 patients with PD, randomly assigned into two equal groups. Group 1 received ESWT (Dornier Medtech GmbH, Germany, D82234 Wessling, 62 Argelsrieder Feld, 7, Germany (FSZ 2011/09554) on the penis, targeting the fibrotic areas and calcifications twice weekly for 6 weeks. Group 2 underwent 2 visits per week for 6 weeks. Visit 1 involved PRP injections and ESWT on the penis, fibrotic areas, and calcifications. Visit 2 included only ESWT on the same areas. Outcomes were assessed on days 0 and 60 (median (IQR%)) using the Peyronie’s Disease Questionnaire (PDQ), Visual Analog Scale (VAS) during sexual intercourse and erection, penile curvature angle, plaque size, and calcifications based on penile ultrasound. Results: the treatment was well tolerated by all patients. No side effects were recorded. In group 2, one patient experienced disease progression, developing a «hourglass» deformity of the penis. Both groups showed significant reductions in pain and PD symptoms, as measured by VAS during erection (p = 0.001028, p < 0.001) and VAS during sexual intercourse (p = 0.01604, p < 0.001), as well as improvement in PDQ scores (p < 0.001, p < 0.001). The penile curvature angle also significantly decreased in both groups (p = 0.02364, p = 0.007346). While the size and number of calcifications decreased slightly (p > 0.05), the fibrotic plaque area showed significant regression in both groups (p = 0.001929, p = 0.003188). Post-treatment analysis showed a significant difference in plaque size reduction, VAS during erection, and during sexual intercourse in favor of patients who received APGF in combination with ESWT (p < 0.05). Conclusion: PRP and ESWT may represent a promising conservative strategy for treating PD. Combined therapy of APGF and ESWT is more effective in reducing pain and fibrotic plaque size in the penis compared to ESWT alone. Keywords: Peyronie’s disease, platelet rich plasma, extracorporeal shock wave therapy, growth factors, regenerative medicine, erectile dysfunction.